We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+6.27%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.02B
AUM Growth
-$45.6M
Cap. Flow
-$64.3M
Cap. Flow %
-6.32%
Top 10 Hldgs %
45.69%
Holding
126
New
39
Increased
20
Reduced
28
Closed
30

Top Buys

Rank Stock Value
1
BTAI icon
BioXcel Therapeutics
BTAI
+$12.6M
2
JNJ icon
Johnson & Johnson
JNJ
+$11.8M
3
GNRC icon
Generac Holdings
GNRC
+$11M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$10.6M
5
LLY icon
Eli Lilly
LLY
+$10.2M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$41.2M
2
NVO
Novo Nordisk
NVO
+$26.2M
3
NICE icon
Nice
NICE
+$14.2M
4
FVRR icon
Fiverr
FVRR
+$11.8M
5
QTTB icon
Q32 Bio
QTTB
+$10M

Sector Composition

Rank Sector Weight
1 Healthcare 70.42%
2 Technology 5.67%
3 Consumer Discretionary 2.57%
4 Industrials 2.19%
5 Communication Services 1.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MSFT icon
26
Microsoft
MSFT
$3.45T
$10.8M 1.06%
51,278
-30,686
-37% -$6.45M
ALLT icon
27
Allot
ALLT
$372M
$9.51M 0.93%
1,045,337
+81,881
+8% +$866K
KRNT icon
28
Kornit Digital
KRNT
$705M
$9.3M 0.91%
143,381
-33,126
-19% -$1.9M
TRIL
29
DELISTED
Trillium Therapeutics Inc.
TRIL
$9.17M 0.9%
645,435
-532,911
-45% -$5.31M
META icon
30
Meta Platforms (Facebook)
META
$1.42T
$9.17M 0.9%
+35,000
New +$9.03M
NBP
31
NovaBridge Biosciences American Depositary Shares
NBP
$185M
$8.55M 0.84%
+181,820
New +$5.99M
IMTX icon
32
Immatics
IMTX
$1.18B
$8.49M 0.83%
+800,000
New +$8.43M
IOVA icon
33
Iovance Biotherapeutics
IOVA
$1.82B
$8.33M 0.82%
253,000
-95,000
-27% -$2.91M
FROG icon
34
JFrog
FROG
$9.66B
$8.08M 0.79%
+95,415
New +$7.1M
FVRR icon
35
Fiverr
FVRR
$321M
$7.96M 0.78%
57,301
-109,701
-66% -$11.8M
KRYS icon
36
Krystal Biotech
KRYS
$10.1B
$7.95M 0.78%
184,573
+40,000
+28% +$1.74M
WVE icon
37
Wave Life Sciences
WVE
$1.09B
$7.91M 0.78%
931,200
+638,200
+218% +$7M
RPTX
38
DELISTED
Repare Therapeutics
RPTX
$7.54M 0.74%
245,000
– –
SNDX icon
39
Syndax Pharmaceuticals
SNDX
$1.69B
$7.53M 0.74%
510,000
+290,000
+132% +$4.42M
FATE icon
40
Fate Therapeutics
FATE
$286M
$7.51M 0.74%
188,000
-37,000
-16% -$1.29M
FISV
41
Fiserv Inc
FISV
$28.8B
$7.24M 0.71%
70,246
-25,000
-26% -$2.49M
BURL icon
42
Burlington
BURL
$23.2B
$7.21M 0.71%
+35,000
New +$6.82M
VRNS icon
43
Varonis Systems
VRNS
$4.59B
$6.95M 0.68%
+180,675
New +$6.74M
DPZ icon
44
Domino's
DPZ
$11.5B
$6.9M 0.68%
16,221
+1,700
+12% +$677K
ALXO icon
45
ALX Oncology
ALXO
$261M
$6.87M 0.68%
+182,070
New +$7.16M
ZNTL icon
46
Zentalis Pharmaceuticals
ZNTL
$337M
$6.37M 0.63%
+194,996
New +$6.83M
VRNA
47
DELISTED
Verona Pharma
VRNA
$6.24M 0.61%
+1,000,000
New +$6.91M
ITOS
48
DELISTED
iTeos Therapeutics
ITOS
$6.17M 0.61%
+250,000
New +$6.72M
IMVT icon
49
Immunovant
IMVT
$7.93B
$5.98M 0.59%
170,000
+65,000
+62% +$1.95M
ALBO
50
DELISTED
Albireo Pharma Inc
ALBO
$5.79M 0.57%
+173,600
New +$5.06M
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2020 Portfolio in Review

As of Q3 2020, Sphera Funds Management held 126 positions worth $1.02B, down 4.3% from $1.06B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Sphera Funds Management withdrew a net $64.3M in Q3 2020, closing 30 positions and reducing 28 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $41.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 64% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Sphera Funds Management opened a new position in BioXcel Therapeutics worth $11.7M.

  • Sphera Funds Management's largest Q3 2020 buy was BioXcel Therapeutics: 16,831 shares worth $11.7M.
  • Sphera Funds Management added most to Johnson & Johnson in Q3 2020, an estimated $11.8M increase.
  • Sphera Funds Management's biggest Q3 2020 reduction was Nice, cutting an estimated $14.2M.
  • Sphera Funds Management fully exited Bristol-Myers Squibb in Q3 2020, selling an estimated $41.2M.
  • Sphera Funds Management's ten largest holdings make up 46% of its $1.02B portfolio in Q3 2020.
  • Sphera Funds Management opened 39 new positions and closed 30 in Q3 2020.
  • Sphera Funds Management's portfolio value fell 4.3% quarter-over-quarter to $1.02B.

Based on Sphera Funds Management's 13F filing for Q3 2020, filed 12 Nov 2020.